European Pharmacopoeia (Ph. Eur.)
The pharmacopoeia that sets quality standards for medicines in Europe, published by the European Directorate for the Quality of Medicines. Ph. Eur. monographs for peptide products define testing methods, specifications, and reference standards applicable across all European countries.
Technical Context
The Ph. Eur. is published by the European Directorate for the Quality of Medicines (EDQM), part of the Council of Europe (broader than the EU — 39 member states plus the EU). Ph. Eur. standards are legally binding in all signatory states. Structure: general notices (overarching rules), general monographs (applying to categories — e.g. 'Products of Recombinant DNA Technology'), specific monographs (individual substances), and general chapters (methods and reagents). For peptide drugs, Ph. Eur. includes monographs for: somatropin for injection (specifying HPLC purity, isoform ratio, host cell protein limits, DNA limits, and bioassay), oxytocin, vasopressin, calcitonin-salmon, insulin preparations, and many antimicrobial peptides. The Certification of Suitability (CEP) procedure allows drug substance manufacturers to demonstrate compliance with Ph. Eur. monographs — a CEP simplifies the quality section of marketing authorisation applications.